We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Rapid Ebola Virus Detection Assay Evaluated

By LabMedica International staff writers
Posted on 17 Nov 2015
Ebolavirus (EBOV) infection is mainly diagnosed by various in-house and commercial real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays used in up to 38 laboratories implemented at or close to Ebola treatment centers (ETC) in West Africa.

Transmission of Ebolavirus disease (EVD) occurs almost exclusively from human to human by direct contact with body fluids of symptomatic cases. More...
Consequently, the control strategy for EVD epidemics relies on early identification of EBOV-infected patients and corpses for, respectively, isolation and safe burials.

An international team of scientists led by those at the Institut Pasteur de Dakar (Dakar, Senegal) evaluated a new nucleic acid extraction kit on sera and swabs in combination with an improved diagnostic reverse transcription recombinase polymerase amplification assay for the detection of Ebolavirus (EBOV-RT-RPA) that was compared in parallel to other methods. Serum samples from acute cases and cheek and tongue swabs from deceased were collected. In addition, following an upsurge of EVD cases connected to funeral rites, oral swabs from all deceased were tested at the morgue.

The extraction kit tested was the SpeedXtract Nucleic Acid Kit (SE), (Qiagen; Hilden, Germany). The W-PCR was performed on the SmartCycler (Cepheid; Sunnyvale, CA, USA) using the RNA Master Hybridisation Probes kit (Roche; Manheim, Germany). A mobile laboratory was used which consisted of a glovebox, a Diagnostics-in-a-Suitcase (DiaS), and a solar panel and power pack set. The RT-RPA was performed using a custom-made EBOV-specific exo RT kit with pellets containing optimized enzyme concentrations.

The EBOV-RT-RPA was evaluated in comparison to two real-time PCR assays. The prevalence of EBOV in the swabs tested was 12.9%. The day of death after onset of disease peaked at day 6 (range: 2 to14 days) in the group of 67 swab-positive deceased for whom disease symptoms were recorded. Of 928 post-mortem swabs, 120 tested positive, and the combined SE and EBOV-RT-RPA yielded a sensitivity and specificity of 100% in reference to one real-time RT-PCR assay. Another widely used real-time RT-PCR was much less sensitive than expected. Results were provided very fast within 30 to 60 minutes, and the field deployment of the mobile laboratory helped improve burial management and community engagement.

Related Links:

Institut Pasteur de Dakar  
Qiagen
Cepheid



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.